Researchers awarded £1.5m for national dementia inequalities network
The ESRC EquaDem Network Plus aims to improve disparities in diagnosis and care
Read More
Tag: University of Liverpool
University of Liverpool launches new biotech spin-out company Galytx
The biotech company will develop novel therapeutic drugs for the treatment of fatal diseases
Read More
UK lung cancer study demonstrates further evidence on importance of CT screening
Currently the third most common cancer in the UK, lung cancer affects 40,000 people annually
Read More
Liverpool and McMaster University announce £300,000 strategic research partnership
Areas include health research across life stages, from paediatrics to health ageing and resilience
Read More
Unitaid funds over £6m to Liverpool researchers to treat major diseases
The project aims to advance therapeutics for tuberculosis, malaria and hepatitis C in LMICs
Read More
University of Liverpool to lead £125m research facility supported by UKRI investment
Set to open in 2032, the RUEDI facility is funded by the UKRI’s recent infrastructure fund worth £388m
Read More
Cambridge researchers redesign future mRNA therapeutics
One-third of patients who received Pfizer’s COVID-19 vaccine had unintended immune responses
Read More
Johns Hopkins study shows potential for chemical vaccine against malaria
Malaria was responsible for over 600,000 worldwide deaths in 2021
Read More
New clinical trial platform launched to accelerate COVID-19 treatments
AGILE is a ‘proof of confidence engine’ designed to quickly identify the most promising compounds for treatment of COVID-19
Read More
Groups hails potential of organ on a chip tech for UK
The Medicines Discovery Catapult, the Centre for Drug Safety Sciences at the University of Liverpool and the National Centre for the Replacement Refinement & Reduction of Animals in Research are working together to “propel” the UK into the race to advance organ on a chip technology.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
